Literature DB >> 8423236

Lovastatin inhibits proliferation of rat mesangial cells.

M P O'Donnell1, B L Kasiske, Y Kim, D Atluru, W F Keane.   

Abstract

Products of intracellular mevalonate metabolism are essential for cell growth and proliferation. Lovastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, blocks the formation of mevalonate and its metabolites, and has been shown to inhibit proliferation of several cell types. In vivo, lovastatin has reduced mesangial cellularity and glomerular injury in experimental renal disease. In this study, we investigated the effects of lovastatin on DNA replication and proliferation in rat glomerular mesangial cells. Growth-arrested mesangial cells were exposed to medium containing 10% fetal bovine serum to stimulate mitogenesis. Lovastatin (1-20 microM) caused a significant (P < 0.05) dose-dependent reduction in DNA synthesis ([3H]thymidine incorporation) which was completely prevented in the presence of exogenous mevalonate (100 microM). Lovastatin (1 microM) inhibited cell proliferation by 90% over a 5-d period, and this was largely overcome by added mevalonate. Exogenous low density lipoprotein (100 micrograms/ml) did not prevent lovastatin inhibition of DNA synthesis. The isoprenoid end product isopentenyl adenine (5 or 50 microM) had little effect on DNA synthesis and cell proliferation in lovastatin-blocked cells. By contrast, the isoprenoid farnesol (5 microM) largely prevented lovastatin inhibition of DNA synthesis. We conclude that mevalonate metabolism is essential for mesangial cell proliferation, possibly through the production of the isoprenoid farnesol. Moreover, the action of lovastatin to reduce experimental glomerular injury may involve a direct effect on mesangial cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8423236      PMCID: PMC329998          DOI: 10.1172/JCI116204

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

Review 1.  Structural and functional properties of ras proteins.

Authors:  E Santos; A R Nebreda
Journal:  FASEB J       Date:  1989-08       Impact factor: 5.191

Review 2.  Regulation of the mevalonate pathway.

Authors:  J L Goldstein; M S Brown
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

3.  Post-translational modification of low molecular mass GTP-binding proteins by isoprenoid.

Authors:  W A Maltese; K M Sheridan; E M Repko; R A Erdman
Journal:  J Biol Chem       Date:  1990-02-05       Impact factor: 5.157

4.  Role of mevalonic acid in the regulation of natural killer cell cytotoxicity.

Authors:  J L Cutts; T J Scallen; J Watson; A D Bankhurst
Journal:  J Cell Physiol       Date:  1989-06       Impact factor: 6.384

5.  Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin.

Authors:  H Y Pan; A R DeVault; D Wang-Iverson; E Ivashkiv; B N Swanson; A A Sugerman
Journal:  J Clin Pharmacol       Date:  1990-12       Impact factor: 3.126

6.  Lovastatin blocks N-ras oncogene-induced neuronal differentiation.

Authors:  C E Mendola; J M Backer
Journal:  Cell Growth Differ       Date:  1990-10

7.  Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation.

Authors:  J H Jackson; C G Cochrane; J R Bourne; P A Solski; J E Buss; C J Der
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

8.  All ras proteins are polyisoprenylated but only some are palmitoylated.

Authors:  J F Hancock; A I Magee; J E Childs; C J Marshall
Journal:  Cell       Date:  1989-06-30       Impact factor: 41.582

9.  p21ras is modified by a farnesyl isoprenoid.

Authors:  P J Casey; P A Solski; C J Der; J E Buss
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

10.  PDGF induction of tyrosine phosphorylation of GTPase activating protein.

Authors:  C J Molloy; D P Bottaro; T P Fleming; M S Marshall; J B Gibbs; S A Aaronson
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

View more
  17 in total

1.  Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin.

Authors:  S R Husain; P Gill; R J Kreitman; I Pastan; R K Puri
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

2.  Therapeutics in renal disease: the road ahead for antiproliferative targets.

Authors:  Peter J Nelson; Stuart J Shankland
Journal:  Nephron Exp Nephrol       Date:  2005-12-07

Review 3.  Are there potential non-lipid-lowering uses of statins?

Authors:  D C Wheeler
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

4.  Cathepsin L activity correlates with proteinuria in chronic kidney disease in humans.

Authors:  Yu Cao; Xing Liu; Ying Li; Yao Lu; Hua Zhong; Weihong Jiang; Alex F Chen; Timothy R Billiar; Hong Yuan; Jingjing Cai
Journal:  Int Urol Nephrol       Date:  2017-05-22       Impact factor: 2.370

5.  Alterations in cell cholesterol content modulate Ca(2+)-induced tight junction assembly by MDCK cells.

Authors:  M C Stankewich; S A Francis; Q U Vu; E E Schneeberger; R D Lynch
Journal:  Lipids       Date:  1996-08       Impact factor: 1.880

6.  Antiproliferative effect of fluvastatin and thiazolidinedione in mesangial cells of diabetic rats.

Authors:  Mitsuru Okada; Hidehiko Yanagida; Hiroaki Kuwajima; Tsukasa Takemura
Journal:  Pediatr Nephrol       Date:  2003-11-22       Impact factor: 3.714

Review 7.  Hyperlipidemia in childhood nephrotic syndrome.

Authors:  M A Thabet; J R Salcedo; J C Chan
Journal:  Pediatr Nephrol       Date:  1993-10       Impact factor: 3.714

8.  The combination of lovastatin and enalapril in a model of progressive renal disease.

Authors:  B H Brouhard; H Takamori; S Satoh; S Inman; M Cressman; K Irwin; V Berkley; N Stowe
Journal:  Pediatr Nephrol       Date:  1994-08       Impact factor: 3.714

9.  Mevalonate availability affects human and rat resistance vessel function.

Authors:  J B Roullet; H Xue; C M Roullet; W S Fletcher; M J Cipolla; C T Harker; D A McCarron
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

10.  Adolescent type 1 Diabetes Cardio-renal Intervention Trial (AdDIT).

Authors: 
Journal:  BMC Pediatr       Date:  2009-12-17       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.